Phase 3 Endometrial Cancer Trial, Recruiting NCT05367206 Sponsor: Sun Yat-sen University Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 3 Endometrial Cancer Trial, Recruiting

NCT05367206
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a confirmed type of cervical cancer — specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  • People whose cancer has been classified as FIGO (2018) stage IIIC, with a tumour larger than 4 cm and/or a lymph node larger than 2 cm at the time of first diagnosis
  • People aged between 18 and 70 years old
  • People who have a general health and activity level that falls within a certain range, measured by a standard medical scoring system called the ECOG performance scale (scores 0 to 2, meaning able to carry out at least some daily activities) (confirm with trial site)
  • People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements (confirm with trial site)

Who may not be able to join:

  • People who are not at the stage of their first diagnosis — for example, those whose cancer has returned or who have already received treatment
  • People who have another type of cancer in addition to cervical cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 020-87343817

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
14 March 2022
Est. completion
31 March 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

3-year progression-free survival ratio

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov